We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

T:NYSEAT&T Inc. Analysis

Data as of 2026-06-13 - not real-time

$23.58

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

AT&T is trading at $23.58, well below its 20‑day (≈24.1), 50‑day (≈25.3) and 200‑day (≈26.2) moving averages, signaling a bearish short‑term technical backdrop. The RSI sits at 42, indicating neutral momentum, while a bearish MACD histogram and a price hovering near the $22.32 support level reinforce downside pressure; however, volume is increasing and the 30‑day volatility is elevated at roughly 25%, though the stock’s beta is modestly negative, suggesting limited market‑wide correlation.
Fundamentally, AT&T appears markedly undervalued with a trailing P/E of 7.8 versus an industry average near 17, a solid dividend yield of 4.7% and a payout ratio under 40%, both pointing to dividend sustainability. Strong operating cash flow ($38.8 B) and free cash flow ($8.8 B) support the 18% ROE, while leverage is high (debt‑to‑equity >125) but offset by sizable cash reserves. Analysts rate the stock as a “buy” with a median target around $31, implying ~28% upside, and the recent Rivian 5G partnership adds a growth narrative amid an “Extreme Greed” market sentiment.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price testing strong support at $22.32
  • bearish MACD and SMA alignment
  • high dividend yield provides downside buffer

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • undervalued valuation with P/E ~7.8 vs industry ~17
  • analyst consensus target ~ $31 indicating ~28% upside
  • Rivian 5G partnership expands growth potential

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • stable cash generation and sustainable dividend
  • strong ROE and defensive telecom sector positioning
  • long‑run upside to target price and value‑oriented profile

Key Metrics & Analysis

Financial Health

Revenue Growth2.90%
Profit Margin16.94%
P/E Ratio7.8
ROE18.37%
ROA4.12%
Debt/Equity125.17
P/B Ratio1.5
Op. Cash Flow$38.8B
Free Cash Flow$8.8B
Industry P/E17.0

Technical Analysis

TrendBearish
RSI42.0
Support$22.32
Resistance$25.43
MA 20$24.09
MA 50$25.29
MA 200$26.20
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Target Price$30.28
Upside/Downside28.42%
GradeUndervalued
TypeValue
Dividend Yield4.71%

Risk Assessment

Beta-0.25
Volatility25.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.